Article
Haemophilia A: mutation type determines risk of inhibitor formation.
Thrombosis and haemostasis - 1 Dec 1995
Schwaab R, Brackmann H H, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham E G, Oldenburg J
Abstract excerpt
The formation of factor VIII antibodies is a major problem for replacement therapy of haemophilia A patients. Antibodies occur in 5-30% of patients with severe haemophilia A. The reason for antibody formation is still unknown. In this study we correlate for the first time different factor VIII gene mutations, stop- and missense mutations, large and small deletions and intrachromosomal intron 22 recombinations to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.